| HCA |
Report |
Q2 Revenue |
IN-LINE |
pred ~$20.23B vs. cons ~$20.2B |
HIGH |
| HCA |
Report |
Q2 Adjusted EPS |
IN-LINE |
pred ~$7.59 (dil. $7.62) vs. cons ~$7.60 |
HIGH |
| HCA |
Report |
Q2 Adjusted EBITDA |
IN-LINE |
pred ~$4.03B vs. cons ~$4.03B |
HIGH |
| HCA |
Guide |
FY2026 Adjusted EPS guidance |
UNCHANGED |
guide ~$28.70-30.50 (mid $29.60) vs. cons ~$29.60 (FY2026) |
HIGH |
| HCA |
Guide |
FY2026 Adjusted EBITDA guidance |
UNCHANGED |
guide ~$15.40-16.10B (mid $15.75B) vs. cons ~$15.75B (FY2026) |
HIGH |
| HCA |
Guide |
FY2026 Revenue guidance |
UNCHANGED |
guide ~$77.0-79.5B (mid $78.25B) vs. cons ~$78.2B (FY2026) |
MEDIUM |
| HCA |
Guide |
FY2026 ACA exchange headwind assumption |
UNCHANGED |
guide ~$1.0-1.2B vs. cons ~$1.1B (FY2026, already reset 7/14) |
MEDIUM |
| HCA |
Guide |
2027 annualized EPTC/exchange headwind (call commentary — swing factor) |
UNKNOWN |
implied ~$1.5-2.0B annualized vs. cons ~$1.2B (FY2027) |
MEDIUM |
| HCA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.0% |
— |
LOW |
| HCA |
Return |
5-day cumulative residual |
-0.5% (STABILIZE) |
All headline numbers and the FY26 guide cut were pre-announced 7/14 (stock -7% then +3.6% off the low into the print), so the call carries no new hard numbers — it is a pure narrative event. A modest day-1 relief tick is plausible as the flush is done, expectations are reset, and buybacks provide a floor. But the structural EPTC/uninsured overhang into 2027 and ongoing sector-wide estimate trims cap follow-through, while the completed flush limits further downside — net range-bound. Downside skew only if management previews a materially worse-than-feared 2027 exchange annualization. |
LOW |